IL313115A - R1–IGF monoclonal antibodies and their use - Google Patents

R1–IGF monoclonal antibodies and their use

Info

Publication number
IL313115A
IL313115A IL313115A IL31311524A IL313115A IL 313115 A IL313115 A IL 313115A IL 313115 A IL313115 A IL 313115A IL 31311524 A IL31311524 A IL 31311524A IL 313115 A IL313115 A IL 313115A
Authority
IL
Israel
Prior art keywords
compound
acid
alkyl
optionally substituted
group
Prior art date
Application number
IL313115A
Other languages
English (en)
Hebrew (he)
Inventor
Eric Steven Burak
Ryan Wayne Simms
John Fitzmaurice Valliant
John Richard Forbes
Matthew David Burr Moran
Darwish Alla
Original Assignee
Centre For Probe Dev And Commercialization
Eric Steven Burak
Ryan Wayne Simms
John Fitzmaurice Valliant
John Richard Forbes
Matthew David Burr Moran
Darwish Alla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre For Probe Dev And Commercialization, Eric Steven Burak, Ryan Wayne Simms, John Fitzmaurice Valliant, John Richard Forbes, Matthew David Burr Moran, Darwish Alla filed Critical Centre For Probe Dev And Commercialization
Publication of IL313115A publication Critical patent/IL313115A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1036—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IL313115A 2017-05-05 2018-05-04 R1–IGF monoclonal antibodies and their use IL313115A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502288P 2017-05-05 2017-05-05
US201762545945P 2017-08-15 2017-08-15
PCT/US2018/031233 WO2018204872A2 (en) 2017-05-05 2018-05-04 Igf-1r monoclonal antibodies and uses thereof

Publications (1)

Publication Number Publication Date
IL313115A true IL313115A (en) 2024-07-01

Family

ID=64016737

Family Applications (2)

Application Number Title Priority Date Filing Date
IL313115A IL313115A (en) 2017-05-05 2018-05-04 R1–IGF monoclonal antibodies and their use
IL270457A IL270457B2 (en) 2017-05-05 2018-05-04 R1–IGF monoclonal antibodies and their use

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL270457A IL270457B2 (en) 2017-05-05 2018-05-04 R1–IGF monoclonal antibodies and their use

Country Status (15)

Country Link
US (2) US11433148B2 (enExample)
EP (1) EP3638320A4 (enExample)
JP (2) JP7191938B2 (enExample)
KR (2) KR20200004861A (enExample)
CN (1) CN110891614A (enExample)
AU (2) AU2018261890B2 (enExample)
BR (1) BR112019023249A8 (enExample)
CA (1) CA3062538A1 (enExample)
CL (1) CL2019003169A1 (enExample)
IL (2) IL313115A (enExample)
MA (1) MA49398A (enExample)
MX (1) MX2024006675A (enExample)
RU (1) RU2019139434A (enExample)
WO (1) WO2018204872A2 (enExample)
ZA (1) ZA201908072B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110891614A (zh) * 2017-05-05 2020-03-17 融合制药公司 Igf-1r单克隆抗体及其用途
IL270453B2 (en) 2017-05-05 2025-05-01 Fusion Pharmaceuticals Inc Pharmacokinetic enhancements of bifunctional chelates and uses thereof
IL319835A (en) 2017-12-06 2025-05-01 Avidity Biosciences Inc Compositions and methods for treating muscular dystrophy and myotonic dystrophy
MA54401A (fr) * 2018-12-03 2021-10-13 Fusion Pharmaceuticals Inc Polythérapie associant des radioimmunoconjugués et des inhibiteurs de réparation des dommages à l'adn
AU2020367415A1 (en) * 2019-10-18 2022-05-19 Nihon Medi-Physics Co., Ltd. RI-labeled humanized antibody
KR20220139883A (ko) * 2020-01-10 2022-10-17 퓨전 파마슈티칼즈 인크. 마크로시클릭 킬레이트 및 그의 용도
AU2021206233A1 (en) * 2020-01-10 2022-08-11 Fusion Pharmaceuticals Inc. Sustained immunotherapy
BR112022019226A2 (pt) * 2020-03-23 2022-11-08 Fusion Pharmaceuticals Inc Radioimunoconjugados direcionados a fgfr3 e usos dos mesmos
WO2021195469A1 (en) 2020-03-27 2021-09-30 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
CN119792512A (zh) * 2020-10-14 2025-04-11 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
US20230084477A1 (en) 2021-08-10 2023-03-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2023049985A1 (en) * 2021-09-29 2023-04-06 National Research Council Of Canada Egfrviii-targeted compounds and uses thereof
EP4423137A1 (en) * 2021-10-25 2024-09-04 Fusion Pharmaceuticals Inc. Claudin 18.2-targeted compounds and uses thereof
CA3237041A1 (en) * 2021-11-02 2023-05-11 Fusion Pharmaceuticals Inc. Methods of treating cancer
EP4577527A1 (en) * 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Vhh antibody dota conjugates
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
WO2024216389A1 (en) * 2023-04-20 2024-10-24 Fusion Pharmaceuticals Inc. Claudin 18.2-targeted compounds and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175343A (en) 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4889931A (en) 1988-09-27 1989-12-26 Salutar, Inc. Manganese (II) chelate manufacture
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990009379A1 (en) 1989-02-10 1990-08-23 Celltech Limited Aza-macrocycles and processes for their preparation
US5053503A (en) 1989-02-17 1991-10-01 Centocor Chelating agents
US6274713B1 (en) 1989-04-07 2001-08-14 Salutar, Inc. Polychelants
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US7385041B2 (en) 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
JPH06340556A (ja) 1990-06-18 1994-12-13 Dow Chem Co:The イメージング剤としての大環状アミノホスホン酸錯体の使用
US5386011A (en) 1990-12-27 1995-01-31 Abbott Laboratories Hexapeptide anaphylatoxin-receptor ligands
GB9112536D0 (en) * 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
CA2134239C (en) 1992-06-09 2004-11-23 Donald B. Axworthy Pretargeting methods and compounds
US5358704A (en) 1993-09-30 1994-10-25 Bristol-Myers Squibb Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents
GB9504922D0 (en) 1995-03-10 1995-04-26 Nycomed As Process
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
IT1291624B1 (it) 1997-04-18 1999-01-11 Bracco Spa Chelati complessi di metalli paramagnetici a bassa tossicita'
IT1304501B1 (it) 1998-12-23 2001-03-19 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza
JP2003501488A (ja) 1999-06-11 2003-01-14 ネオルックス コーポレイション 骨髄抑制のための高投与量放射性核種錯体
DE10002939C1 (de) 2000-01-13 2001-09-20 Schering Ag Paramagnetische DOTA-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung für die Herstellung von pharmazeutischen Mitteln
US20020052354A1 (en) 2000-01-27 2002-05-02 Schering Ag Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction
US6264966B1 (en) 2000-02-22 2001-07-24 Concat, Ltd. Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
AU7748801A (en) 2000-05-12 2002-04-02 Mallinckrodt Inc Prochelators for the preparation of radiometal labeled molecules having improvedbiological properties
AU2002249935A1 (en) 2001-01-08 2002-08-19 Neorx Corporation Radioactively labelled conjugates of phosphonates
EP1385556A4 (en) * 2001-05-02 2005-10-19 Univ Missouri System At Columb PEPTIDE CONJUGATES WITH AFFINITY FOR GASTRIN RECEPTORS
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
DE10135356C1 (de) 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
AU2003261398A1 (en) 2002-08-06 2004-02-23 Epix Pharmaceuticals, Inc. Peptide aggregates
DE10250870A1 (de) 2002-10-31 2004-05-13 Switch Biotech Ag Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung
US20060235296A1 (en) 2003-02-13 2006-10-19 Bracco Imaging S.P.A. Contrast enhanced x-ray phase imaging
SI1603598T1 (sl) 2003-03-19 2009-02-28 Universitaetsspital Basel Radiooznačeni konjugati na osnovi substance P innjihove uporabe
WO2005001415A2 (en) 2003-05-23 2005-01-06 Epix Pharmaceuticals, Inc. Optically pure and enriched isomers of chelating ligands and contrast agents
JP4262545B2 (ja) 2003-07-09 2009-05-13 三菱電機株式会社 カスコード接続回路及びその集積回路
US20070269375A1 (en) * 2003-07-24 2007-11-22 Bracco Imaging S.P.A. Stable Radiopharmaceutical Compositions and Methods for Preparation
JP2007505315A (ja) 2003-09-12 2007-03-08 インヴィトロジェン コーポレーション 多重結合および活性アッセイ
CN100528162C (zh) 2003-12-19 2009-08-19 先灵公司 药物组合物
WO2005079803A1 (en) 2004-02-13 2005-09-01 Pfizer Products, Inc. Compounds for treatment of cardiovascular diseases
WO2006015318A2 (en) 2004-07-30 2006-02-09 Biogen Idec Inc. Antibody conjugated to a drug moiety via a poptidic linker
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US20060222595A1 (en) 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
WO2007009637A2 (de) 2005-07-15 2007-01-25 Bayer Schering Pharma Aktiengesellschaft Deren verwendung als kontrastmittel zur anwendung in der nmr-, rontgen- und radiodiagnostik sowie in der radiotheraphie
US7618957B2 (en) 2005-07-15 2009-11-17 Bayer Schering Pharma Aktiengesellschaft Perfluoroalkyl-containing complexes, process for their production as well as their use
US20100226884A1 (en) 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
WO2007084264A2 (en) 2005-12-29 2007-07-26 Epix Pharmaceuticals, Inc. Methods for myocardial imaging
CA2645666A1 (en) 2006-03-15 2007-09-20 Mallinckrodt Inc. Chelating conjugates having a substituted aromatic moiety and derivatives thereof
SG170799A1 (en) * 2006-03-28 2011-05-30 Biogen Idec Inc Anti-igf-ir antibodies and uses thereof
US7777029B2 (en) 2006-05-02 2010-08-17 San Diego State University (Sdsu) Foundation Bifunctional chelators for sequestering lanthanides
JP2010500417A (ja) 2006-08-11 2010-01-07 ライフ テクノロジーズ コーポレーション センサータンパク質及びアッセイ方法
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
GB0624587D0 (en) 2006-12-08 2007-01-17 Univ Muenchen Tech Chelating agent
US20100111858A1 (en) 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
WO2008134289A2 (en) 2007-04-26 2008-11-06 Mallinckrodt Inc. High relaxivity coordinatively unsaturated lanthanide complexes
ES2676598T3 (es) 2007-08-27 2018-07-23 Liebel-Flarsheim Company Llc Eliminación de sílice a partir de compuestos hidrosolubles mediante nanofiltración y cromatografía en fase inversa
CA2697612A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
EP2100900A1 (en) * 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
JP2011516549A (ja) * 2008-04-11 2011-05-26 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗ｉｇｆ−１ｒ抗体と他の化合物との治療的併用
DE102008045937B4 (de) 2008-04-11 2017-01-26 Johannes-Gutenberg-Universität Mainz Radiopharmakon aus einem Metallion und einem Markierungsvorläufer und Verwendung des Radiopharmakons
WO2010009246A2 (en) 2008-07-16 2010-01-21 The General Hospital Corporation Methods and reagents for preparing multifunctional probes
EP2147684A1 (en) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
JP2012507573A (ja) 2008-11-06 2012-03-29 ルイーザ ブラッチ、 ニューロテンシン誘導分岐ペプチドおよびその使用
WO2010088527A2 (en) 2009-01-30 2010-08-05 Mayo Foundation For Medical Education And Research Peptides and nanoparticles for therapeutic and diagnostic applications
EP2408790A1 (en) 2009-03-19 2012-01-25 Wyeth LLC Methods for the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid and precursors thereof
CA2766409C (en) * 2009-07-03 2023-04-25 Avipep Pty Ltd Immuno-conjugates and methods for producing them
WO2011005609A2 (en) 2009-07-08 2011-01-13 Mayo Foundation For Medical Education And Research Imaging gastrointestinal volumes and motility
WO2011079315A1 (en) 2009-12-23 2011-06-30 The Scripps Research Institute Tyrosine bioconjugation through aqueous ene-like reactions
EP2525820B1 (en) 2010-01-19 2016-05-11 Immunomedics, Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
EP2397466B1 (en) 2010-06-15 2012-11-28 Centre National De La Recherche Scientifique CNRS X-ray and gamma-photon activatable organic compounds, their preparation and their uses
US9573978B2 (en) 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
JP6063384B2 (ja) * 2010-10-14 2017-01-18 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． プレターゲットキット、プレターゲット方法及びその使用試薬
US12097269B2 (en) 2010-10-27 2024-09-24 Vikas Kundra Dual mode gadolinium nanoparticle contrast agents
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
US20140088019A1 (en) * 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
US8685916B2 (en) 2011-03-09 2014-04-01 Signature Therapeutics, Inc. Opioid prodrugs with heterocyclic linkers
DK2721045T3 (en) 2011-06-20 2017-07-24 Radiomedix Inc COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS
FR2976825B1 (fr) 2011-06-22 2014-02-21 Total Sa Nanotraceurs pour le marquage d'eaux d'injection de champs petroliers
EP2604281B1 (en) 2011-12-14 2014-07-30 Centre National de la Recherche Scientifique (CNRS) Clicked somatostatin conjugated analogs for biological applications
KR20130083592A (ko) 2012-01-13 2013-07-23 현대약품 주식회사 치환된 피페리딘 유도체 및 이의 제조방법
EP2852685A1 (en) * 2012-03-30 2015-04-01 Merck Sharp & Dohme Corp. Igf1 biomarker for igf1r inhibitor therapy
SG11201408150UA (en) 2012-06-14 2015-01-29 Janssen Biotech Inc Treatment of pluripotent cells
CN102743770B (zh) 2012-06-18 2017-07-21 申宝忠 一种靶向性分子成像探针及活体分子成像方法
US10039843B2 (en) 2012-09-07 2018-08-07 Bracco Imaging S.P.A. Paramagnetic solid lipid nanoparticles (pSLNs) containing metal amphiphilic complexes for MRI
US9931412B2 (en) 2013-02-08 2018-04-03 The Regents Of The University Of Michigan Targeted theranostics
CA2911259A1 (en) 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
WO2015023979A1 (en) 2013-08-16 2015-02-19 Equip, Llc Discrete peg constructs
US10471163B2 (en) 2013-09-13 2019-11-12 The General Hospital Corporation Activatable fibrin-binding probes
KR101947053B1 (ko) 2013-10-18 2019-02-12 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원（ｐｓｍａ）의 표지된 억제제, 조영제로서의 이의 용도 및 전립선암 치료용 약제
WO2015073575A2 (en) 2013-11-12 2015-05-21 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
CN105939732A (zh) 2013-12-03 2016-09-14 通用医疗公司 分子成像探针
FR3015547B1 (fr) 2013-12-20 2016-01-01 Total Sa Methode pour ajuster le taux d'inhibiteurs dans un puits de petrole ou de gaz
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
DK3129406T3 (en) 2014-04-11 2019-04-01 Medimmune Llc CONJUGATED COMPOUNDS INCLUDING CYSTEIN MODIFIED ANTIBODIES
EP3134127B1 (en) 2014-04-25 2020-02-26 Rinat Neuroscience Corp. Antibody-drug conjugates with high drug loading
EP3142710A4 (en) 2014-05-16 2018-04-25 Memorial Sloan Kettering Cancer Center One-step labeling of antibodies to high specific activity with actinium-225
EP3180037A1 (en) 2014-07-29 2017-06-21 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
BE1021191B1 (fr) 2014-08-29 2015-10-27 Anmi S.A. Kit pour radiomarquage.
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
DE102014115154A1 (de) 2014-10-17 2016-04-21 SCV-SpezialChemikalien-Vertrieb GmbH Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen
EA037590B1 (ru) 2014-11-25 2021-04-19 Бристол-Майерс Сквибб Компани Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации
WO2017120193A1 (en) 2016-01-04 2017-07-13 University Of Kansas Drug delivery compositions and methods
US10758634B2 (en) * 2016-03-18 2020-09-01 Wake Forest University Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography
CN110891614A (zh) * 2017-05-05 2020-03-17 融合制药公司 Igf-1r单克隆抗体及其用途
IL270453B2 (en) * 2017-05-05 2025-05-01 Fusion Pharmaceuticals Inc Pharmacokinetic enhancements of bifunctional chelates and uses thereof
US10093741B1 (en) * 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
CA3190855A1 (en) * 2020-08-27 2022-03-03 Joe Mccann Radiopharmaceutical and methods
KR20240121775A (ko) * 2021-11-26 2024-08-09 풀-라이프 테크놀로지스 에이치케이 리미티드 세포 표면 수용체를 표적화하는 절단 가능 방사성 리간드 및 이의 용도

Also Published As

Publication number Publication date
CN110891614A (zh) 2020-03-17
ZA201908072B (en) 2023-04-26
JP2023025209A (ja) 2023-02-21
US20230052140A1 (en) 2023-02-16
EP3638320A4 (en) 2021-01-20
IL270457B1 (en) 2024-07-01
KR20240160664A (ko) 2024-11-11
EP3638320A2 (en) 2020-04-22
IL270457A (enExample) 2020-01-30
MX2024006675A (es) 2024-06-24
JP7191938B2 (ja) 2022-12-19
WO2018204872A3 (en) 2018-12-13
MA49398A (fr) 2020-04-22
CL2019003169A1 (es) 2020-08-14
AU2018261890A1 (en) 2019-11-28
NZ759831A (en) 2025-05-30
US20190083662A1 (en) 2019-03-21
WO2018204872A2 (en) 2018-11-08
RU2019139434A3 (enExample) 2021-06-17
US11433148B2 (en) 2022-09-06
BR112019023249A8 (pt) 2021-02-23
CA3062538A1 (en) 2018-11-08
KR20200004861A (ko) 2020-01-14
AU2025204253A1 (en) 2025-06-26
JP2020518674A (ja) 2020-06-25
RU2019139434A (ru) 2021-06-07
BR112019023249A2 (pt) 2020-06-02
AU2018261890B2 (en) 2025-03-20
IL270457B2 (en) 2024-11-01

Similar Documents

Publication Publication Date Title
US20230052140A1 (en) Igf-1r monoclonal antibodies and uses thereof
CA3062553C (en) Pharmacokinetic enhancements of bifunctional chelates and uses thereof
US20230270895A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
US10093741B1 (en) IGF-1R monoclonal antibodies and uses thereof
US11793895B2 (en) Residualizing linkers and uses thereof
US20240285818A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
US20240408249A1 (en) Egfrviii-targeted compounds and uses thereof
EA045310B1 (ru) Моноклональные антитела к igf-1r и их применение
EA045232B1 (ru) Усиление фармакокинетики бифункциональных хелатов и их применения